Comparison of the initial and residual speed of Ixodes scapularis kill on dogs treated with a single dose of Bravecto ® Chew (25 mg/kg fluralaner) or Simparica TRIO ® (1.2 mg/kg sarolaner, 24 µg/kg moxidectin, 5 mg/kg pyrantel).

Autor: Reif KE; Department of Diagnostic Medicine/Pathobiology, Kansas State University, Manhattan, KS, 66506, USA. kreif@vet.k-state.edu., Bickmeier NP; Department of Diagnostic Medicine/Pathobiology, Kansas State University, Manhattan, KS, 66506, USA., Herrin BH; Department of Diagnostic Medicine/Pathobiology, Kansas State University, Manhattan, KS, 66506, USA., Dryden MW; Department of Diagnostic Medicine/Pathobiology, Kansas State University, Manhattan, KS, 66506, USA., Normile DM; Merck Animal Health, 2 Giralda Farms, Madison, NJ, 07940, USA., Jesudoss Chelladurai JRJ; Department of Diagnostic Medicine/Pathobiology, Kansas State University, Manhattan, KS, 66506, USA., Miller KR; Department of Diagnostic Medicine/Pathobiology, Kansas State University, Manhattan, KS, 66506, USA., Flowers MR; Department of Diagnostic Medicine/Pathobiology, Kansas State University, Manhattan, KS, 66506, USA., Kang Q; Department of Statistics, Kansas State University, Manhattan, KS, 66506, USA.
Jazyk: angličtina
Zdroj: Parasites & vectors [Parasit Vectors] 2023 Nov 27; Vol. 16 (1), pp. 440. Date of Electronic Publication: 2023 Nov 27.
DOI: 10.1186/s13071-023-05946-3
Abstrakt: Background: Compliant ectoparasiticide product use is a comprehensive way to control ticks and reduce the risk of tick-borne pathogen transmission to dogs. Because the systemically acting isoxazoline ectoparasiticides require tick attachment for drug delivery, fast speed of kill is essential to minimize tick-borne pathogen transmission risk.
Methods: Dogs of satisfactory tick-carrying capacity were randomly allocated to treatment groups and administered, per label instructions, Bravecto ® Chews (minimum 25 mg/kg fluralaner), Simparica TRIO ® (minimum 1.2 mg/kg sarolaner, 24 µg/kg moxidectin, 5 mg/kg pyrantel), or no treatment. Dogs were infested with approximately 50 unfed adult (35 female, 15 male) Ixodes scapularis on Day -2, 21 and 28. Live tick counts were performed at 4, 8, 12 and 24 h post-treatment (Day 0) and post-infestation on Day 21 and 28. Tick control efficacy was determined by comparing live tick means for each product-treated group to the untreated control group and each other at all time points using a linear mixed model. The percent of dogs free of live ticks was analyzed using the Fisher's exact test for treatment group comparison.
Results: The untreated control group maintained adequate tick infestations throughout the study. Using geometric means, an existing I. scapularis infestation was controlled by 99.7% and 93.0% 12 h post-treatment and by 100% and 99.5% 24 h post-treatment, for Bravecto ® and Simparica TRIO ® -treated dogs, respectively. Ixodes scapularis infestations were controlled more quickly for Bravecto ® - compared to Simparica TRIO ® -treated dogs on Day 21 at 8 h (efficacy 74.0% vs. 0.0%, p = 0.003) and 12 h (efficacy 99.2% vs. 39.4%, p < 0.001) post-infestation and Day 28 at 8 h (efficacy 92.2% vs. 0.0%, p < 0.001) and 12 h (efficacy 99.6% vs. 27.7%, p < 0.001) post-infestation. On Day 28 post-treatment, the efficacy of Bravecto ® and Simparica TRIO ® to control a new I. scapularis infestation was 100% and 96.6%, respectively, by 24 h post-infestation. Of product-treated dogs, 100% of Bravecto ® -treated dogs were free of live ticks by 24 h post-treatment or post-infestation. No treatment-related adverse reactions occurred during the study.
Conclusions: Ixodes scapularis infestations are controlled more quickly 21 and 28 days post-treatment for dogs administered a single dose of Bravecto ® compared to dogs administered a single dose of Simparica TRIO ® .
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz: